CCR9 and neoplasm: In addition to expected immunoregulatory hits, such as CD274 (PD-L1) and LGALS3 (Galectin-3), knockdown of C-C chemokine receptor type 9 (CCR9), GLI pathogenesis-related 1 like 1 (GLIPR1L1), growth hormone secretagogue receptor (GHSR) and carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) enhanced tumour cell lysis across multiple malignant cell lines.